Literature DB >> 15312961

Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation.

Lars N G Nilsson1, Gary W Arendash, Ralph E Leighty, David A Costa, Mark A Low, Marcos F Garcia, Jennifer R Cracciolo, Amyn Rojiani, Xin Wu, Kelly R Bales, Steven M Paul, Huntington Potter.   

Abstract

Biochemical and genetic studies indicate that the inflammatory proteins, apolipoprotein E (ApoE) and alpha(1)-antichymotrypsin (ACT) are important in the pathogenesis of Alzheimer's disease (AD). Using several lines of multiply transgenic/knockout mice we show here that murine ApoE and human ACT separately and synergistically facilitate both diffuse A beta immunoreactive and fibrillar amyloid deposition and thus also promote cognitive impairment in aged PDAPP(V717F) mice. The degree of cognitive impairment is highly correlated with the ApoE- and ACT-dependent hippocampal amyloid burden, with PDAPP mice lacking ApoE and ACT having little amyloid and little learning disability. A analysis of young mice before the onset of amyloid formation shows that steady-state levels of monomeric A beta peptide are unchanged by ApoE or ACT. These data suggest that the process or product of amyloid formation is more critical than monomeric A beta for the neurological decline in AD, and that the risk factors ApoE and ACT participate primarily in disease processes downstream of APP processing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312961     DOI: 10.1016/j.neurobiolaging.2003.12.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  28 in total

1.  Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease.

Authors:  Anna Lord; Ola Philipson; Therése Klingstedt; Gunilla Westermark; Per Hammarström; K Peter R Nilsson; Lars N G Nilsson
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice.

Authors:  Tim D Boyd; Steven P Bennett; Takashi Mori; Nicholas Governatori; Melissa Runfeldt; Michelle Norden; Jaya Padmanabhan; Peter Neame; Inge Wefes; Juan Sanchez-Ramos; Gary W Arendash; Huntington Potter
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice.

Authors:  Anna Lord; Hillevi Englund; Linda Söderberg; Stina Tucker; Fredrik Clausen; Lars Hillered; Marcia Gordon; Dave Morgan; Lars Lannfelt; Frida E Pettersson; Lars N G Nilsson
Journal:  FEBS J       Date:  2009-02       Impact factor: 5.542

4.  USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE.

Authors:  Lars N G Nilsson; Sylvia Gografe; David A Costa; Tiffany Hughes; David Dressler; Huntington Potter
Journal:  Technol Innov       Date:  2012-02-01

Review 5.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

6.  Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis.

Authors:  Carsten W Lederer; Antonietta Torrisi; Maria Pantelidou; Niovi Santama; Sebastiano Cavallaro
Journal:  BMC Genomics       Date:  2007-01-23       Impact factor: 3.969

7.  Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease.

Authors:  M Ilyas Kamboh; Ryan L Minster; Margaret Kenney; Ayla Ozturk; Purnima P Desai; Candace M Kammerer; Steven T DeKosky
Journal:  Neurobiol Aging       Date:  2005-08-30       Impact factor: 4.673

8.  Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity.

Authors:  Jennifer R Cracchiolo; Takashi Mori; Stanley J Nazian; Jun Tan; Huntington Potter; Gary W Arendash
Journal:  Neurobiol Learn Mem       Date:  2007-08-21       Impact factor: 2.877

9.  Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?

Authors:  Bruno P Imbimbo; Vincenzo Solfrizzi; Francesco Panza
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

Review 10.  Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

Authors:  Yadong Huang; Robert W Mahley
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.